Access PROSTOX Testing
PROSTOX TESTING ACCESS
To help prostate cancer patients avoid toxicity
Stereotactic Body Radiation Therapy (SBRT) for prostate cancer treatment is a form of radiation treatment that is convenient, effective, and generally well-tolerated.
However, 15-20% of men will experience side effects that may start 6 months or longer after treatment, with the most common side effects affecting the urinary system. These side effects are referred to as late genitourinary (GU) toxicity.
PROSTOX is a simple DNA test that will tell you and your physician if you are at a low or high risk for late GU toxicity. Knowing this risk can allow you and your doctor to choose the safest course of treatment for you.
PROSTOXTM Testing
Testing performed by MiraDX, patient access through MiraKind.
You are eligible to order PROSTOX testing through MiraKind if all of the following apply to you:
- You have a prostate cancer diagnosis
- You have not received radiation treatment to the prostate
- You are considering Stereotactic Body Radiation Therapy (SBRT) for prostate cancer
- You agree to participate in a MiraKind PROSTOX research registry.
$500*
*Cost of testing through MiraKind only. If you need further financial assistance, apply here.
Questions? Read our PROSTOX FAQ or Contact us
Understanding your PROSTOX results
Once your results are ready, you will need to discuss them with a physician.
People being treated with SBRT for prostate cancer have on average a 15-20% chance of experiencing late GU side effects following SBRT. PROSTOX tests a patient's DNA and risk stratifies them - PROSTOX can determine if they are at a High risk or Low risk of developing late GU toxicities.If a patient is found to be High risk, they have an 80% chance of developing late GU toxicity, whereas if they are Low risk they have only a 4% risk of late GU toxicity.1,2,3
Questions? Read our PROSTOX FAQ or Contact us
Frequently asked questions about MiraDX PROSTOXTM testing through MiraKind
General questions about PROSTOX
Accessing PROSTOX through MiraKind
Taking the test
Participating in our research registry
Disclosure: Any discussion of medical management options is for general informational purposes only and does not constitute a medical recommendation. All medical management decisions should be made based on consultation between each patient and his or her healthcare professional.
References
- Kishan AU, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Network Open 2019;2:e188006.
- Weidhaas, JB, et al. MicroRNA-based biomarkers of the radiation response in prostate cancer. Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020) 163-163. DOI: 10.1200/JCO.2020.38.6_suppl.163.
- Kishan AU, et al. Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. Journal for Radiotherapy and Oncology 2022;167:226-232. doi: 10.1016/j.radonc.2021.12.040.
